Our Story
We teach people how to understand psychedelics safely and responsibly — through real data, structured education, and harm reduction.
Born From a Belief in Natural Healing
Paradise Farmers Market was founded in 2022 by a collective in the DMV with over a decade of mycology experience. Our founder's journey spanned years of hands-on study and global exploration — learning the rich history and benefits of fungi, from culinary traditions to therapeutic applications.
What we saw was clear: millions of people were suffering, and the treatments available weren't working for everyone. In 2021, an estimated 21 million U.S. adults experienced a major depressive episode. About 39% did not receive treatment for depression that year.
We started Paradise because we believe these communities deserve better options and better information. Not hype. Not misinformation. Real, research-backed education that empowers people to make informed decisions about their own wellness.
The Crisis That Drives Us
Destigmatize. Educate. Advocate.
We are building a structured education platform focused on psychedelic literacy, harm reduction, and public awareness — bridging the gap between community-level knowledge and institutional understanding with accessible, evidence-informed resources.
We translate peer-reviewed science into content everyone can understand. We host community events, publish guides, and build tools, including our 142-entry strain library, a collection of sample-specific lab reports, and an interactive legislation map tracking all 50 states.
How We Got Here
A Decade of Study
Over 10 years studying mycology — exploring the history and benefits of fungi across the globe.
Initiative 81 Passes
D.C. voters approve Initiative 81 with 76.18% of votes cast on the measure.
Paradise Is Founded
PFM launches in the DMV — advocates, educators, and mycology experts united.
A Growing Movement
142 strains documented, education hub, community events, and educational content informed by peer-reviewed research.
Research-Backed Education
Based in Maryland, we follow research from Johns Hopkins and other institutions. In a small randomized study published in 2020, 24 adults with major depressive disorder completed two psilocybin sessions with supportive psychotherapy. Four weeks after the intervention, 17 participants (71%) had at least a 50% reduction in depression scores. These findings apply to a screened, supported research setting and do not establish the same outcomes for unsupervised use.
From clinical trials on psilocybin for depression to research on consciousness and well-being, we translate peer-reviewed science into accessible education for everyone.
2020 JAMA Psychiatry studyJohns Hopkins Research
- ◆Center for Psychedelic and Consciousness Research established in 2019.
- ◆Research includes psilocybin-assisted therapy for depression.
- ◆In one small trial, 71% responded at four weeks after two supported sessions.
- ◆Results depend on the study population, methods and follow-up.
Rooted in the D.C. Community
In November 2020, D.C. voters approved Initiative 81, the Entheogenic Plant and Fungus Policy Act of 2020, with 76.18% of votes cast on the measure. The law directs the Metropolitan Police Department to treat investigation and arrest for specified non-commercial activities involving entheogenic plants and fungi by adults 18 and older as among its lowest enforcement priorities. It does not legalize possession, sales or commercial distribution. Our D.C. educational work includes explaining Initiative 81 and its limits.
We host workshops, educational events, and community gatherings that demystify psilocybin and empower people with the knowledge they need for safe, responsible decision-making.
Initiative 81 (D.C.)
- ◆Applies to specified non-commercial activities by adults 18 and older.
- ◆Among MPD’s lowest enforcement priorities, not immunity from arrest.
- ◆Does not legalize possession, sales or commercial distribution.
- ◆Approved with 76.18% of votes cast on the measure in 2020.
Our Commitments
Knowledge Over Commerce
We exist to educate, not to sell. Every resource we publish is designed to help people make informed, evidence-based decisions about their own wellness.
Ethical Operations
Transparency, integrity, and respect for legal frameworks guide everything we do. We advocate for responsible, legal pathways and explain the limits of Initiative 81.
Harm Reduction Focus
Safety is non-negotiable. We promote risk awareness, evidence-based harm reduction practices, and informed decision-making without advocating for substance use.
Community Responsibility
We are accountable to our members and the broader public. Our membership review process is intended to support a respectful learning community.
Learn More
Understanding the Research
Researchers are studying psilocybin with psychological support for several mental-health conditions. Some studies report benefits, but findings depend on the participants, treatment setting and follow-up period. Psilocybin can also cause adverse effects and is not suitable for everyone. Research findings should not be treated as a recommendation to self-treat or replace prescribed care.
We believe destigmatization starts with education. Paradise exists to share this research and empower everyone with knowledge — not to sell, but to inform.
NCCIH: Psilocybin for mental health and addiction